Retatrutide Stacks and Combinations: What the Research Literature Covers

Questions about combining retatrutide with other compounds — most often testosterone — appear frequently in search data. This page describes what each compound is in regulatory and pharmacological terms, summarises what the published retatrutide literature reported when the drug was studied on its own, and states plainly what the literature does and does not contain about co-administration. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision. Nothing here is legal advice either.

What the Search Question Actually Asks

The phrase "retatrutide and testosterone together" bundles two very different categories of compound. Retatrutide is an investigational injectable peptide that activates three metabolic hormone receptors. Testosterone is the principal endogenous androgen in humans and, in the United States, the active ingredient in several FDA-approved prescription products used for male hypogonadism; testosterone is also a Schedule III controlled substance. Retatrutide, by contrast, has not been approved by any major regulator as of the publications summarised below, and material sold online under that name is frequently labelled research-use-only rather than as a medicine.

Because the two sit in different regulatory categories and were developed for entirely different indications, they have never appeared together in a published clinical protocol. The sections that follow separate what was actually studied from what is being asked.

What Retatrutide Is

Retatrutide (development code LY3437943) is a single-molecule agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. Its discovery, preclinical characterisation and first-in-human pharmacology were described in a 2022 report that traced the molecule from design through early clinical proof of concept, where researchers reported glycaemic and body-weight effects consistent with combined activity at all three receptors. Narrative reviews have since framed the triple-agonist mechanism as an attempt to add glucagon-receptor signalling — associated with energy expenditure and hepatic lipid handling — to the incretin effects already exploited by GLP-1 and dual GIP/GLP-1 drugs, as summarised in one 2024 pharmacology review and a 2025 overview.

Early-phase and phase 2 findings

A phase 1b multiple-ascending-dose trial in people with type 2 diabetes tested weekly subcutaneous administration against placebo; the study reported dose-related reductions in glycated haemoglobin and body weight alongside predominantly gastrointestinal adverse events. A subsequent phase 2 trial in type 2 diabetes compared retatrutide at 0.5 mg, 4 mg, 8 mg and 12 mg weekly with placebo and an active comparator over 36 weeks, and researchers reported dose-dependent improvements in glycaemic control together with weight reduction.

The most widely cited dataset is a 48-week phase 2 obesity trial. Adults with obesity, or with overweight plus at least one weight-related condition, were randomly assigned to placebo or retatrutide at doses from 1 mg up to 12 mg once weekly using several escalation schedules. At 48 weeks, the study reported a least-squares mean body-weight change of −24.2% in the 12 mg group compared with −2.1% with placebo.

Liver fat, body composition and comparative analyses

A phase 2a randomised trial in participants with metabolic dysfunction-associated steatotic liver disease reported substantial reductions in liver fat content with retatrutide relative to placebo, as described in that 2024 report. A separate body-composition substudy nested in the phase 2 type 2 diabetes programme used imaging to quantify tissue changes; researchers reported that weight lost comprised reductions in fat mass along with smaller reductions in lean mass. That substudy is the single most relevant published document to the testosterone question, because lean-mass change during rapid weight loss is the reason many readers raise androgens at all — yet the substudy itself administered no androgen.

Aggregate analyses have compared retatrutide with other agents rather than combining them. A Bayesian network meta-analysis of GLP-1 receptor agonists, dual agonists and retatrutide reported retatrutide among the highest-ranking interventions for weight reduction in adults with overweight or obesity. A systematic review and meta-analysis of randomised trials similarly reported efficacy for weight and metabolic endpoints alongside a mainly gastrointestinal adverse-event profile.

Phase 3 programmes

Later-stage testing is ongoing and, again, monotherapy-based. A double-blind phase 3 trial in people with type 2 diabetes inadequately controlled with diet and exercise (TRANSCEND-T2D-1) evaluated retatrutide against comparator treatment, with results reported in 2026. The rationale and design of the TRIUMPH registrational programme, covering obesity, obstructive sleep apnoea and knee osteoarthritis, were described separately. None of these designs, as published, involved co-administration with androgens or with other peptides.

What Testosterone Is, in This Context

Testosterone is an endogenous steroid hormone produced principally by the testes in men and in smaller quantities by the ovaries and adrenal glands. Approved testosterone products exist in injectable, transdermal, buccal, nasal and oral formulations and are indicated for specific hypogonadal conditions; prescribing, monitoring and controlled-substance handling are governed by national regulation. No paper in the verified evidence set for this page examined testosterone, so this page makes no claims about its effects, doses or safety profile. Readers looking for that information would need to consult the endocrinology literature and a licensed clinician.

Did Any Published Study Examine the Combination?

No. Across the retatrutide literature summarised above — the discovery and phase 1 report, the phase 1b and phase 2 diabetes trials, the phase 2 obesity trial, the MASLD phase 2a trial, the body-composition substudy, the phase 3 diabetes trial, the published TRIUMPH design paper, and two quantitative syntheses — every design was retatrutide versus placebo, versus an active comparator drug, or versus other incretin-based agents across trials. There is no published randomised trial, no published pharmacokinetic interaction study, and no published case series in which retatrutide was administered together with testosterone, with an anabolic-androgenic steroid, or with another peptide such as a growth-hormone secretagogue.

That absence matters in a specific technical sense. Because no study co-administered them, the literature contains no data on whether the combination alters pharmacokinetics, no data on additive or offsetting effects on body composition, no data on adverse-event frequency under co-administration, and no monitoring framework derived from trial experience. Statements found online about how the two "work together" are therefore extrapolations from separate bodies of evidence, not findings.

Why the Question Keeps Coming Up

Several threads converge on this search, and understanding them explains the volume without supplying evidence that does not exist.

• Lean mass during large weight reductions. The magnitude of weight change reported in the phase 2 obesity trial — a least-squares mean of −24.2% at 48 weeks at the highest dose versus −2.1% with placebo (the study) — prompted public discussion about tissue composition. The nested body-composition substudy in type 2 diabetes reported that both fat mass and lean mass declined, which fuels speculation about anabolic co-treatment even though no such co-treatment was tested.
• Overlapping patient populations. Obesity, type 2 diabetes and low measured testosterone frequently coexist in the same men, so people already receiving androgen therapy under medical supervision naturally ask how an investigational metabolic drug would fit alongside it. The verified literature does not address that question.
• Marketplace framing. Retatrutide circulates in grey-market research-chemical channels where unrelated compounds are listed side by side, which creates an impression of established "protocols" that has no basis in published trials.
• Analogy from other incretin drugs. Approved GLP-1 and dual-agonist medicines are routinely used alongside other prescriptions in clinical practice, and readers generalise from that to retatrutide. The network meta-analysis that included retatrutide compared agents against one another; it did not evaluate any of them in combination.

Adverse Events in Retatrutide Trials: What Studies Report

Safety information in the published record describes retatrutide given alone. The phase 2 obesity trial reported that the most common adverse events were gastrointestinal — including nausea, diarrhoea, vomiting and constipation — that these were mostly mild to moderate, and that they occurred more often during dose escalation. The phase 2 type 2 diabetes trial reported a broadly similar pattern, and the phase 1b multiple-ascending-dose trial also reported gastrointestinal events as the predominant tolerability issue. A systematic review and meta-analysis of randomised trials summarised these gastrointestinal signals across studies while reporting weight and metabolic efficacy.

Because no study co-administered retatrutide with testosterone or any other compound discussed here, none of these tolerability observations can be extended to a combination scenario. Adverse-event rates observed under monotherapy conditions describe monotherapy conditions only.

What Would Be Needed Before Any Combination Could Be Described

Readers tracking this literature can watch for specific document types rather than commentary. A dedicated drug–drug interaction study would characterise whether one agent alters the exposure of the other. A randomised factorial or add-on design would separate the contribution of each component to body composition or metabolic endpoints. Registrational programmes such as TRIUMPH, whose design rationale was published in 2026, specify their permitted background medications in protocol documents, which is where any future co-administration data would first surface. Until documents of that kind exist, the honest description of the combination question is that it is unstudied.

Limitations of the Current Evidence

Even for retatrutide alone, the evidence base is young. Most detailed efficacy data come from phase 2 trials of 36 to 48 weeks, with phase 3 reporting only beginning, as with the double-blind trial in type 2 diabetes published in 2026. Reviews of the molecule have noted that long-term outcome data, durability after discontinuation and use in broader populations remain open questions (2025 overview; 2024 review). Where monotherapy evidence is still maturing, combination evidence is necessarily further behind.

This page describes published findings and does not recommend, endorse or discourage any use of any compound, alone or together. Decisions about medications belong with a licensed physician who can assess an individual's history.

References

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (Lancet, 2022)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (The Lancet Diabetes & Endocrinology, 2025)
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA (Obesity, 2025)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings, Baylor University Medical Center, 2025)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (Lancet, 2026)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• The power of three: Retatrutide's role in modern obesity and diabetes therapy (European Journal of Pharmacology, 2024)